---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Prevalence"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Prevalence. Topics: U.S. prevalence in 2023, all prostate cancer stages; Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020; Metastatic disease among men living with prostate cancer, modeled U.S. estimate for 2009; Prior androgen receptor pathway inhibitor before metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/prevalence"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="topic-2.2.1.2.2-1"></a>

### U.S. prevalence in 2023, all prostate cancer stages

> “In 2023, there were an estimated 3,700,086 men living with prostate cancer in the United States.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.2-2"></a>

### Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020

| Clinical state | Prevalence, 2009 | Prevalence, 2020 projection |
| --- | --- | --- |
| Asymptomatic or minimally symptomatic mCRPC not treated with or not progressed on chemotherapy | “6745” | “8320” |
| Symptomatic mCRPC not treated with or not progressed on chemotherapy | “32,145” | “39,650” |
| mCRPC that progressed on or after first-line chemotherapy | “23,220” | “28,720” |

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.2.2-3"></a>

### Metastatic disease among men living with prostate cancer, modeled U.S. estimate for 2009

> “Of these, 2,121,650 (95.6%) presented with localized or locally advanced disease while 97,630 (4.4%) had metastatic prostate cancer (corresponding to non-castrate and mCRPC states).”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.2.2-4"></a>

### Prior androgen receptor pathway inhibitor before metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023

> “Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.”
> “The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.”
> “Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-2.2.1.2.2-5"></a>

### Prior abiraterone for metastatic hormone-sensitive disease and androgen receptor pathway inhibitor reuse, U.S. ConcertAI cohort 2020 to 2023

> “Among 609 people identified, the most common prior treatment for mHSPC was androgen deprivation therapy (ADT) alone (53%); others included ADT plus abiraterone (ABI; 19%), ADT plus a non-ABI androgen receptor pathway inhibitor (ARPI; 18%) and ADT plus docetaxel (10%).”
> “Among those who received ADT plus ABI or a non-ABI ARPI for mHSPC, 50% and 40%, respectively, also received an ARPI 1L for mCRPC.”

Source: [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/)

<a id="topic-2.2.1.2.2-6"></a>

### Prior novel hormonal therapy and sequential novel hormonal therapy, Medicare fee-for-service cohort 2014 to 2019

> “Ten per cent of patients had undergone NHT use prior to their mCRPC diagnosis, and 3% had previously been treated with taxane-based chemotherapy.”
> “The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.1.2.2-7"></a>

### Androgen receptor pathway inhibitor sequencing across real-world studies

> “ARPI-to-ARPI from the first to the second line was the most common sequence in the US studies.”

Source: [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
